Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
Status:
Recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out if radiation therapy followed by intrathecal
trastuzumab and pertuzumab is safe and will result in improved survival in HER2 positive
breast cancer which has metastasized to the leptomeninges.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute